253 related articles for article (PubMed ID: 33167494)
21. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
22. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
23. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
24. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
25. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Cedrés S; Felip E; Cruz C; Martinez de Castro A; Pardo N; Navarro A; Martinez-Marti A; Remon J; Zeron-Medina J; Balmaña J; Llop-Guevara A; Miquel JM; Sansano I; Nuciforo P; Mancuso F; Serra V; Vivancos A
J Natl Cancer Inst; 2018 Aug; 110(8):914-917. PubMed ID: 29529211
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
Strait KA; Warnick CT; Ford CD; Dabbas B; Hammond EH; Ilstrup SJ
Mol Cancer Ther; 2005 Apr; 4(4):603-11. PubMed ID: 15827334
[TBL] [Abstract][Full Text] [Related]
27. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
[TBL] [Abstract][Full Text] [Related]
28. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
29. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.
To KKW; Fu LW
Invest New Drugs; 2018 Feb; 36(1):10-19. PubMed ID: 28819699
[TBL] [Abstract][Full Text] [Related]
30. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
31. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
[TBL] [Abstract][Full Text] [Related]
32. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Stenzel K; Hamacher A; Hansen FK; Gertzen CGW; Senger J; Marquardt V; Marek L; Marek M; Romier C; Remke M; Jung M; Gohlke H; Kassack MU; Kurz T
J Med Chem; 2017 Jul; 60(13):5334-5348. PubMed ID: 28581289
[TBL] [Abstract][Full Text] [Related]
33. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
34. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Gueugnon F; Cartron PF; Charrier C; Bertrand P; Fonteneau JF; Gregoire M; Blanquart C
Oncotarget; 2014 Jun; 5(12):4504-15. PubMed ID: 24980825
[TBL] [Abstract][Full Text] [Related]
35. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
[TBL] [Abstract][Full Text] [Related]
36. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells.
Chu SH; Liu YW; Zhang L; Liu B; Li L; Shi JZ; Li L
Mol Biol Rep; 2013 Jan; 40(1):1-6. PubMed ID: 23135731
[TBL] [Abstract][Full Text] [Related]
37. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
38. Adenosine enhances cisplatin sensitivity in human ovarian cancer cells.
Sureechatchaiyan P; Hamacher A; Brockmann N; Stork B; Kassack MU
Purinergic Signal; 2018 Dec; 14(4):395-408. PubMed ID: 30078088
[TBL] [Abstract][Full Text] [Related]
39. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
40. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]